Sensitive NMR Approach for Determining the Binding Mode of Tightly Binding Ligand Molecules to Protein Targets

Wan-Na Chen,[†] Christoph Nitsche,[†,‡] Kala Bharath Pilla,[†] Bim Graham,[§] Thomas Huber,[†] Christian D. Klein,[‡] and Gottfried Otting*,[†]

[†]Australian National University, Research School of Chemistry, Canberra, ACT 2601, Australia

[‡]Medicinal Chemistry, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany

[§]Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia

Ⓢ *Supporting Information*

ABSTRACT: Structure-guided drug design relies on detailed structural knowledge of protein−ligand complexes, but crystallization of cocomplexes is not always possible. Here we present a sensitive nuclear magnetic resonance (NMR) approach to determine the binding mode of tightly binding lead compounds in complex with difficult target proteins. In contrast to established NMR methods, it does not depend on rapid exchange between bound and free ligand or on stable isotope labeling, relying instead on a *tert*-butyl group as a chemical label. *tert*-Butyl groups are found in numerous protein ligands and deliver an exceptionally narrow and tall ^{1}H NMR signal. We show that a *tert*-butyl group also produces outstandingly intense intra- and intermolecular NOESY cross-peaks. These enable measurements of pseudocontact shifts generated by lanthanide tags attached to the protein, which in turn allows positioning of the ligand on the protein. Once the ligand has been located, assignments of intermolecular NOEs become possible even without prior resonance assignments of protein side chains. The approach is demonstrated with the dengue virus NS2B-NS3 protease in complex with a high-affinity ligand containing a *tert*-butyl group.

■ INTRODUCTION

Structure-guided ligand design is a powerful approach in drug discovery. Usually, the approach relies on X-ray crystallography to obtain the 3D structural information on the protein−ligand complexes required to guide further ligand development. NMR spectroscopy is often used to aid this process when single crystals of the protein−ligand complexes cannot be obtained. As the NMR resonances of ligand molecules are often difficult to discriminate against the background of protein NMR signals, however, NMR spectroscopic methods tend to perform best for weakly binding and rapidly exchanging ligands that can be used in large excess over the protein.[1] In the case of tightly binding ligands, the ligand molecule can, for all intent and purpose, be considered to act like an integral part of the protein.

The most common NMR approaches to characterize the complexes between proteins and tightly binding ligands involve chemical shift perturbations[2] and nuclear Overhauser effects (NOE).[3] Both methods rely on the assignment of a large number of NMR signals. In particular, reliable assignments of intermolecular NOESY cross-peaks require either near-complete resonance assignments of the target protein, which are difficult to obtain for large target proteins irrespective of the availability of ^{15}N or ^{13}C-labeled protein samples, or information from independent data, such as site-directed mutagenesis experiments.[4] Detailed structural interpretation of chemical shift perturbations is difficult and requires measurements with a series of ligand derivatives.

In recent years, paramagnetic NMR methods have increasingly been recruited for structural analysis of protein−ligand complexes, in particular by making use of paramagnetic relaxation enhancements (PRE) and pseudocontact shifts (PCS) generated by site-specifically attached tags.[5] While much work has focused on these parameters for the analysis of weakly binding complexes,[6−12] the ligand PCSs are exceedingly small if a large excess of ligand is used. The reverse experiment, generating PCSs in the target protein by attaching a paramagnetic metal complex to the ligand, requires a significant chemical modification of the ligand and comprehensive resonance assignments of the protein for data interpretation.[13,14] Examples are rare where PCSs have been used to establish the structure and orientation of a tightly binding ligand at its binding site on the protein.[11,15−17] The fundamental problem in these cases arises from the difficulty in identifying the resonances of the tightly bound ligand. In the special situation of a protein−protein complex, isotope labeling allows selective observation of either protein component, which has been used for structure analysis of high-affinity protein−

protein complexes using PCSs induced by paramagnetic lanthanide ions.[15,17] In the case of a small-molecule ligand, however, synthesis of an isotope-labeled version would usually be prohibitively laborious. An alternative strategy employs selective suppression of the ^{1}H NMR spectrum of the protein by isotope labeling, either using ^{15}N/^{13}C-labeling in combination with half-filter pulse sequences,[18] or by perdeuteration of the protein.[19] Either approach is imperfect, as the half-filters achieve only incomplete suppression of the protein NMR signals, due to nonuniform one-bond coupling constants, and are associated with significant signal decay by relaxation, while very high deuteration levels are required to reduce the residual protein ^{1}H NMR signals to a level below those of the ligand. Instead of relying on costly isotope labeling, the present approach makes use of the unique NMR properties of *tert*-butyl groups.

The ^{1}H NMR signal of a *tert*-butyl group is an intense singlet with a chemical shift in the range of about 1.0 to 1.5 ppm depending on the chemical environment. Owing to rapid methyl rotation and methyl reorientation within this flexible group, the signal of a solvent-exposed *tert*-butyl group is much narrower than protein ^{1}H NMR signals, enabling its detection even in protein complexes of high molecular mass without any isotope labeling.[20] In experiments aimed at probing chemical exchange phenomena, we observed that the *tert*-butyl group also produces NOESY cross-peaks that are much more intense than anticipated and can be observed even under conditions where cross-peaks of the protein are barely detectable. This opens a new route to characterize the binding mode of a ligand labeled with a *tert*-butyl group. First, the NOESY cross-peaks with the *tert*-butyl signal enable measurements of PCSs induced by paramagnetic tags attached to the protein at different sites. These data position the *tert*-butyl group with respect to the protein. If intraligand NOEs with the *tert*-butyl group can be observed, the PCSs of additional ligand protons can be used to orient the ligand in its binding site. Finally, intermolecular NOEs with the *tert*-butyl group further pinpoint its location on the protein.

We demonstrate the approach with the structure determination of the complex between the two-component dengue virus NS2B-NS3 protease (NS2B-NS3pro) from serotype 2 (in the following referred to as DENpro) and a newly developed ligand that contains a boronic acid warhead, binds with high affinity, and contains a *tert*-butyl group (C. Nitsche and C. D. Klein, manuscript in preparation). Although a dengue vaccine has been developed that is effective against all serotypes, the vaccine offers only incomplete protection and is ineffective in children below the age of 6, who need it most.[21] Dengue causes severe complications and is spreading rapidly,[22] making DENpro a drug target of high priority.[23–25] Despite intense efforts over many years, however, crystallization of DENpro remains difficult and only a single structure has been published, which proved to be of an inactive conformation (PDB code 2FOM).[26] Co-crystal structures with inhibitors are available of serotype 3 (PDB code 3U1I and 3U1J)[27] and of the homologous West Nile virus protease,[26] which allow modeling of the structure of DENpro. In the absence of exact structural information, the development of high-affinity inhibitors has been slow. An effective inhibition constant of 43 nM was reported for the peptidic inhibitor Bz-Nle-Lys-Arg-Arg-B(OH)$_2$ owing to the presence of the electrophilic boronic acid warhead which is thought to form a covalent bond to Ser135 at the active site of DENpro.[28] A range of further inhibitors lacking a

boronic acid warhead has been developed,[25,29,30] but their binding modes remain uncertain in the absence of experimental confirmation for any of the computational models built.

DENpro has a molecular mass of about 27 kDa and degrades readily in the absence of high-affinity ligands. Its NMR spectrum shows broad resonances and strong signal overlap, and varies between different constructs and inhibitors.[31–35] The well-resolved ^{15}N-HSQC cross-peaks comprise about half of the backbone amides (Figure S3). We identified three single-cysteine mutants of DENpro for the attachment of paramagnetic lanthanide tags, which generate pronounced PCSs in the NMR spectrum of the protein.[31] Using the resolved ^{15}N-HSQC cross-peaks, PCS measurements are straightforward and allowed characterization of the conformation of DENpro in isolation and in complex with a small-molecule and a protein inhibitor, respectively.[20,31] Assessing the binding mode of the synthetic nonprotein inhibitor, however, proved intractable because of the difficulty in observing and assigning intermolecular NOEs.

In the following we report the binding mode of the high-affinity ligand **1** (Figure 1) to DENpro. This is the first time that the complex between DENpro and a small-molecule ligand

Figure 1. 1D ^{1}H NMR spectra of ligand **1** without and with DENpro. (A) Chemical structure of ligand **1**. Ligand **2** is structurally identical except for the absence of the *tert*-butyl group. (B) 1D ^{1}H NMR spectrum of ligand **1** in the absence of DENpro. The spectrum was recorded at 25 °C in NMR buffer (20 mM MES, pH 6.5, 50 mM NaCl) using a 800 MHz NMR spectrometer. The downfield region of the spectrum was scaled up 8-fold relative to the upfield part of the spectrum. The open arrow marks the ^{1}H NMR resonance of the *tert*-butyl group. The star identifies the signal from an impurity. (C) 1D ^{1}H NMR spectra of 50 μM solutions of DENpro in deuterated NMR buffer without ligand (bottom trace) and in a 1:1 complex with ligand **1** (top trace). The spectral appearance of the aromatic region was simplified by perdeuteration of Tyr, Phe, and Trp. Signals at 7.3 and 8.0 ppm are from the C-terminal His$_6$-tag. The low-field region was scaled up 2-fold relative to the high-field region. The resonance of the *tert*-butyl group of ligand **1** is marked by a filled arrow. The star identifies the signal of a nonbinding impurity.

has been modeled at atomic resolution using experimental NMR data. Importantly, the new protocol succeeded with a limited set of ^{15}N-HSQC cross-peaks of backbone amides, which are sufficiently well resolved to enable a straightforward transfer of their assignments between the free protein and complexes with different inhibitors.

■ MATERIALS AND METHODS

Sample Preparation. Three single-cysteine mutants of DENpro were prepared. The mutants were Ala57*Cys (site A; the asterisk marks residues in NS2B), Ser34Cys (site B), and Ser68Cys (site C). Uniformly ^{15}N-labeled protein samples were produced by over-expression in *E. coli* and selectively isotope-labeled samples by cell-free synthesis as described previously.[31] The samples were ligated with C2-Ln^{3+} tags (Figure S1) as described,[31,35,36] where Ln^{3+} is either Y^{3+}, Tm^{3+}, or Tb^{3+}.

Ligands **1** and **2** were synthesized as described elsewhere (C. Nitsche and C. D. Klein, manuscript in preparation).

NMR Measurements. All NMR spectra were measured on a Bruker 800 MHz NMR spectrometer equipped with a 5 mm TCI cryoprobe, using 3 mm NMR tubes. ^{15}N-HSQC spectra were recorded with t_{1max} = 26.2 ms and t_{2max} = 160 ms. NOESY spectra were recorded with a mixing time of 200 ms, t_{1max} = 58 ms, and t_{2max} = 232 ms. The total recording times of the NOESY spectra varied from 4 h for diamagnetic samples to 8 h for paramagnetic samples.

PCSs were measured as ^{1}H chemical shifts observed for DENpro tagged with C2−Tm^{3+} or C2−Tb^{3+} tags minus the corresponding chemical shifts measured with DENpro tagged with diamagnetic C2−Y^{3+}. PCSs are through-space effects that follow the equation[37]

$$\Delta\delta^{PCS} = 1/(12\pi r^3)[\Delta\chi_{ax}(3\cos^2\theta - 1) + 1.5\Delta\chi_{rh}\sin^2\theta\cos2\varphi] \tag{1}$$

where $\Delta\delta^{PCS}$ is the PCS measured in ppm, r is the distance of the nuclear spin from the metal ion, $\Delta\chi_{ax}$ and $\Delta\chi_{rh}$ are the axial and rhombic components of the magnetic susceptibility anisotropy tensor $\Delta\chi$, and θ and φ are the polar angles describing the position of the nuclear spin with respect to the principal axes of the $\Delta\chi$ tensor. We used the PCSs of backbone amide protons (Table S1) to fit the $\Delta\chi$ tensors to the coordinates of DENpro models generated by Rosetta.[38]

PREs of the *tert*-butyl resonance were measured by comparing its ^{1}H NMR line widths in resolved NOESY cross-peaks recorded for samples tagged with paramagnetic and diamagnetic tags.

Modeling of the Protein−Ligand Complex. A structural model of DENpro in the catalytically active conformation was obtained using the program Modeller[39] and the crystal structure 3U1I[27] of the protease from serotype 3 as the template. A total of 100 models were generated following the advanced modeling protocol,[40] and the best model was selected based on the discrete optimized potential energy (DOPE) score.[41]

The program AutoDock-Vina[42] was used to generate 20 different poses of the docked ligand. Each pose was checked for agreement with the ligand PCSs using six different $\Delta\chi$ tensors, which had been determined from the PCSs of the backbone amides of DENpro with C2−Tm^{3+} and C2−Tb^{3+} tags at three sites. The best-fitting pose was selected for further refinement by the software suite Rosetta[43] to model a covalent bond between the boron and the side chain oxygen of Ser135. Further restraints were introduced to ensure tetrahedral coordination of the boron, as detected in boronic acid complexes of other serine proteases such as the hepatitis C virus protease,[44] and planarity of the guanidinium groups. The all-atom Relax module of Rosetta[43] was used to refine the amino acid side chain conformations in the substrate binding site, following the protocol available in the protocol demonstrations (demos directory) of the Rosetta software suite.[45] From the models generated by the all-atom Relax module, the model that best fulfilled the backbone PCSs of DENpro was selected as the final structure. New $\Delta\chi$ tensors were fitted to each model to find the structure with the lowest PCS score.[46]

■ RESULTS

^{1}H NMR Resonance of the *tert*-Butyl Group of Ligand 1 in the Absence and Presence of DENpro. In the DENpro construct used in the present work, the linker between NS2B and NS3 contained the natural recognition site EVKKQR, leading to autoproteolytic cleavage at this site. We have shown previously that the resulting product assumes the enzymatically active closed conformation of the protease.[35] The unlinked construct degraded during NMR measurements in less than a day, but was stable for months in the presence of ligand **1**.

The 1D ^{1}H NMR spectrum of the free ligand shows four prominent resonances for the aromatic rings between 7 and 8 ppm, and a particularly intense NMR signal for the *tert*-butyl group (Figure 1). The signal of the *tert*-butyl group is also easily discernible in the 1:1 complex with DENpro, whereas the aromatic resonances of the ligand are difficult to identify even in a sample prepared with a high level of perdeuteration of aromatic residues (Tyr, Phe, and Trp). The chemical shift of the *tert*-butyl group of ligand **1** in the bound state is slightly downfield compared with the chemical shift in the free state. In the presence of excess ligand, the signals of bound and free ligand were observed simultaneously, indicating that any chemical exchange is slow as expected for a tightly bound ligand (data not shown).

PCS Measurements. The strategy of the present work relies on PCS measurements of the protein (to determine the $\Delta\chi$ tensors) and of the ligand (to determine the position of the ligand relative to the $\Delta\chi$ tensors and thus relative to the protein). To account for possible conformational changes caused by ligand binding, PCSs of DENpro were measured in ^{15}N-HSQC spectra recorded of the complex between ^{15}N-labeled DENpro and ligand **1**, using C2−Tm^{3+} and C2−Tb^{3+} tags at sites A−C, with C2−Y^{3+} tagged samples as diamagnetic reference (Figures S2−S4). The PCSs were very similar, but not identical, to PCSs measured previously for samples without inhibitor[35] and with the protein inhibitor BPTI.[17] A total of 222 PCSs (Table S1) were measured and used to determine the $\Delta\chi$-tensor parameters (Table S3).

PCSs of the bound ligand **1** sometimes proved difficult to determine from simple 1D ^{1}H NMR spectra. The intense ^{1}H NMR resonance of the *tert*-butyl group was readily detected in the diamagnetic samples, but PREs combined with changes in the NMR spectrum of the protein can make it difficult to identify the resonance in the paramagnetically tagged samples (Figure S5).

In contrast, NOESY spectra turned out to yield intense cross-peaks with the *tert*-butyl resonance that could easily be followed even when the *tert*-butyl resonance was broadened by PRE. In addition, the NOESY spectra yield PCSs not only for the *tert*-butyl resonance itself but also for the protons involved in the NOEs with the *tert*-butyl group. Figure 2B illustrates the intensity of the *tert*-butyl cross-peaks with the wild-type protein. The cross-peaks are readily identified by their narrow line shape in the detection dimension. As expected, they were absent from the corresponding NOESY spectrum recorded with ligand **2**, which is the same as ligand **1** but without the *tert*-butyl group (Figure 2A). Particularly intense cross-peaks are observed with protons at about 7.5 ppm, which were assigned to the aromatic ligand protons in the positions *ortho* and *meta* to the *tert*-butyl group labeled 1, 1′, 2, and 2′ in Figure 1A. (Using a sample prepared with ^{15}N-labeled DENpro, a NOESY spectrum

Figure 2. NOESY spectra of DENpro in complex with ligands **1** and **2**. The spectra were recorded at 25 °C of 150 μM solutions of unlabeled wild-type DENpro in NMR buffer containing 10% D_2O, using 3 mm NMR tubes in a 5 mm TCI cryoprobe. Experimental parameters: 200 ms mixing time, t_{1max} = 58 ms, t_{2max} = 232 ms, total recording time per spectrum 4 h. The spectral region shown captures the NOE cross-peaks of the *tert*-butyl resonance. (A) NOESY spectrum of the complex with ligand **2**. (B) NOESY spectrum of the complex with ligand **1**. Five cross-peaks with the *tert*-butyl resonance are labeled. Note that these cross-peaks were readily detected, while other cross-peaks, e.g., with amide protons, were much weaker or unobservable.

recorded without ^{15}N-decoupling confirmed that these NOEs are not with amide protons of the protein.) Additional cross-peaks at about 0.7 and 1.7 ppm cannot be explained as intraligand NOEs and, based on the chemical shifts, include NOEs with methyl groups.

Figure 3 illustrates the measurement of PCSs from the NOESY cross-peaks with the *tert*-butyl resonance. The cross-peaks were preserved between wild-type DENpro and DENpro tagged with diamagnetic C2−Y^{3+} tags, and were displaced by PCSs in the samples containing paramagnetic tags. Different to backbone amides, where PCSs displace ^{15}N-HSQC cross-peaks along mostly parallel lines owing to the close spatial proximity of ^{1}H and ^{15}N spins, the PCSs observed for the protons involved in NOEs with the *tert*-butyl resonance were mostly different from the PCS of the *tert*-butyl resonance itself, as expected for spins that are located at more disparate positions relative to the $\Delta\chi$ tensors of the paramagnetic tags. Importantly, the C2−Tm^{3+} and C2−Tb^{3+} tags produced PCSs of opposite sign[31,36] and the NOESY cross-peaks of the three samples tagged with C2−Tm^{3+}, C2−Y^{3+}, and C2−Tb^{3+}

Figure 3. PCSs observed in 2D NOESY spectra of DENpro with C2 tags at three different sites. The spectra were recorded of 150 μM solutions of ^{15}N-labeled DENpro complexes with ligand **1** in NMR buffer at 25 °C. The figure shows superimpositions of NOESY spectra for samples tagged with C2−Y^{3+} (black), C2−Tm^{3+} (blue) and C2−Tb^{3+} (red). The spectral regions shown contain cross-peaks between the *tert*-butyl resonance and protons in the aromatic and methyl regions of the NMR spectrum. PCSs are identified by lines drawn between cross-peaks of the diamagnetic samples and their corresponding peaks in the paramagnetic samples. (A) NOESY spectra of the complex tagged at site A. (B) Same as (A), but for the complex tagged at site B. (C) Same as (A), but for the complex tagged at site C. NOEs with two initially unassigned methyl groups are labeled as CH$_3$-1 and CH$_3$-2. The NOEs with two aromatic protons were attributed to the protons 1/1′ and 2/2′ of the ligand (Figure 1A).

tags could be connected by almost straight lines. This greatly aids the identification of the paramagnetically shifted cross-peaks, even when the cross-peaks were significantly broadened by PREs, as for the paramagnetic samples tagged at site B (Figure 3B).

Altogether, the NOESY cross-peaks observed with the *tert*-butyl resonance delivered 18 ligand PCSs together with 14 protein PCSs (Table S2). The ligand PCSs immediately enable a qualitative structural interpretation regarding the orientation of the *tert*-butylphenyl group relative to the $\Delta\chi$ tensors. For example, the PCSs obtained with the tags at site B decrease in magnitude in moving from the protons at positions 2/2′ to those at positions 1/1′ to the *tert*-butyl group (Figure 3B), suggesting that the *tert*-butyl group faces away from the tag at site B. This conclusion is confirmed by the broad line widths of cross-peaks observed for the H-2/2′ resonances in the paramagnetic samples which can be attributed to PREs due to proximity to the tag.

PRE Measurement. As the *tert*-butyl resonance is a singlet, PREs can simply be measured as the difference in line width observed in paramagnetic and diamagnetic samples. The NOESY cross-peaks of Figure 3 clearly show that the *tert*-butyl resonance is broader in the samples with paramagnetic

versus diamagnetic tags, and broader with Tb^{3+} tags than with Tm^{3+} tags, as expected from the greater paramagnetic moment of Tb^{3+}.[47] It is difficult, however, to convert the PREs into quantitative distance restraints from the metal ions. First, the significant anisotropy of the magnetic susceptibility tensors associated with Tb^{3+} and Tm^{3+} needs to be taken into account.[48] Second, the PREs can be compromised by cross-correlation effects with nuclear chemical shift anisotropies.[49] Most importantly, however, the linker of the C2 tag is not entirely rigid, resulting in multiple possible metal positions. For a conservative estimate of the distance restraint indicated by a PRE, we calculated the largest distance compatible with the $\Delta\chi$ tensor anisotropies determined from the PCSs using the anisotropic Curie-spin relaxation equations[48] with a rotational correlation time of 10 ns. We only used the data from site B, which showed the greatest PRE effects (Figure 3). In this construct, the C2−Tb^{3+} and C2−Tm^{3+} tags broadened the *tert*-butyl signal by 22 and 13 Hz, respectively, relative to the diamagnetic sample with the C2−Y^{3+} tag. Both measurements correspond to a distance from the paramagnetic center of about 15.5 Å. To account for the uncertainty in metal position, we converted the PREs observed for mutant B into an upper distance restraint of 20 Å.

PCS-Guided Modeling of the Protein−Ligand Complex. As no crystal structure of DENpro in the active conformation is available and the amino acid sequences of NS2B-NS3pro of serotypes 2 and 3 are 66% sequence identical, we modeled the structure of DENpro on the crystal structure 3U1I of serotype 3.[27] Among 100 very similar homology models, we selected the best model based on the DOPE score,[41] which had a Cα-RMSD of 0.7 Å relative to the crystal structure 3U1I.

The $\Delta\chi$ tensors associated with the C2−Tm^{3+} and C2−Tb^{3+} tags at sites A−C produce different PCSs at different sites of the DENpro-ligand complex. Using the $\Delta\chi$ tensors determined for the best-fitting model of DENpro, we predicted the PCSs for every point of a dense grid placed over the structural model of DENpro to identify all the points that were in agreement with the PCSs generated by the C2−Tm^{3+} and C2−Tb^{3+} tags at sites A−C.

Allowing for an uncertainty range of ±0.02 ppm for the experimental PCSs, the PCSs of the *tert*-butyl group of the ligand identified a continuous space in the vicinity of NS2B, where the *tert*-butyl group could be located. We refer to this PCS-supported grid point volume as localization space. The localization space of the *tert*-butyl group was in full agreement with its expected position upon formation of a covalent bond between Ser135 and the boronic acid moiety of the ligand, as anticipated in the design of the ligand. The localization space shown in Figure 4 was also restricted by imposing the 20 Å distance restraint for the tertbutyl group from the metal position of the tag at site B, which had been derived from PREs.

To generate a complete model of the ligand, 20 poses of ligand 1 were generated on the structural model of DENpro using the program AutoDock-Vina.[42] The different poses produced dramatically different ligand structures and orientations (with a pairwise RMSD of about 10 Å) with very similar calculated binding energies (ranging from −7.5 to −7.9 kcal/mol). The two top-ranked and seven further poses approximately positioned the *tert*-butyl group in the localization space defined by the PCSs. Furthermore, the top-ranked pose positioned the boronic acid group in the vicinity of Ser135 and the direction of the *tert*-butylphenyl group was also in

Figure 4. Model of the complex between DENpro and ligand **1**. NS2B (orange) and NS3pro (gray) are drawn in a cartoon representation, and ligand **1** is shown in a stick representation, displaying hydrogens only for amide and guanidinium groups. Green balls indicate the positions of the lanthanide ions as determined by PCSs for the tags at sites A−C. Meshes identify the localization spaces of the *tert*-butyl group (magenta), protons 1/1′ (purple), and protons 2/2′ (cyan) identified by PCSs from C2−Tm^{3+} and C2−Tb^{3+} tags at sites A−C. The meshes capture localization spaces with PCS deviations smaller than 0.02 ppm from the experimental PCSs.

general agreement with the localization spaces of the 1/1′ and 2/2′ protons (Figure 4). To refine this model of the protein−ligand complex, we used the Rosetta software suite[38,43] to form a covalent bond between the boron of the ligand and the side chain oxygen of Ser135, and allowed small structural adjustments by the all-atom "Relax" refinement protocol of Rosetta. The protocol generated 1000 structures of the complex, all with conserved protein conformations and similar ligand conformations (over 90% within 1.3 Å of the structure with the lowest PCS energy, Figure S6). The protein structure with the lowest PCS score showed an excellent correlation between the experimental and back-calculated PCSs (Figure S7). Figure 4 shows the structure best fulfilling the PCSs of DENpro, which was chosen as the final representation of the DENpro-ligand **1** complex.

The localization spaces of protons 1/1′ and 2/2′ (Figure 4) are progressively closer to the site B, reflecting the large PCSs induced by C2 tags at this site (Figure 3B). This provides strong support for the orientation of the *tert*-butyl phenyl group. The apparent discrepancies between experimental localization spaces and actual proton positions in the model of Figure 4 may arise from mobility of the tag at site B, which can increase the PCSs by transiently shortening the distance between metal and ligand. As PCSs present long-range restraints, experimental uncertainties translate into relatively large uncertainties for localization spaces. Therefore, we used the intermolecular NOEs observed with the *tert*-butyl group to verify the correctness of the model of the complex.

Verification of the Structural Model by Intermolecular NOEs. The model of the complex between DENpro and ligand **1** predicts intermolecular NOEs between the *tert*-butyl group and the methyl groups of Val154 and Val155. The chemical shifts of the NOEs observed with the signals of CH_3-1 and CH_3-2 (Figure 3) agree with expectations for valine methyl groups.

To support this assignment, we recorded a NOESY spectrum of the DENpro-ligand **1** complex in which wild-type DENpro

was selectively labeled with ^{13}C-valine. In the absence of ^{13}C decoupling, the NOESY cross-peaks labeled 1 and 2 in Figure 2 split by $^{1}J_{CH}$ coupling constants and the signal of 3 could no longer be resolved, showing that all three protons indeed belong to valine (Figure S8). To distinguish between Val154 and Val155, we measured a NOESY spectrum of the mutant Val155Ile selectively labeled with ^{13}C-valine. The NOESY cross-peaks observed were in agreement with an isoleucine residue and did not split in the absence of ^{13}C-decoupling, indicating that the NOEs between the *tert*-butyl group of ligand **1** and wild-type DENpro are with Val155 (Figure S9).

■ DISCUSSION

The surprisingly high signal-to-noise ratio of NOESY cross-peaks with a *tert*-butyl group can be attributed to three factors. Most importantly, its ^{1}H NMR resonance is intrinsically narrow because of short effective rotational correlation times arising from fast methyl group rotation and rotation of the *tert*-butyl group. Second, the signal stands out because it corresponds to nine protons. Finally, due to the very strong distance dependence of NOEs, a small population of a short ^{1}H−^{1}H distance can lead to a stronger NOE than a larger population of a slightly longer ^{1}H−^{1}H distance. Therefore, motions of the *tert*-butyl group that transiently shorten the ^{1}H−^{1}H distance can strongly enhance the overall NOE. In this way, NOEs can be observed for proteins of increased molecular weight, which usually display broad ^{1}H NMR lines. In fact, the broad widths of the protein resonances are an advantage in our approach, as this decreases the background of NOESY cross-peaks between other protons. The high sensitivity of the NOESY cross-peaks with the *tert*-butyl resonance enabled their detection in a few hours, using about 100 μM solutions of the complex in 3 mm NMR tubes.

The attempt to use the prominence of the *tert*-butyl resonance in 1D ^{1}H NMR spectra for PCS measurements was compromised by too many spectral changes caused by the paramagnetic tags, including a much broader *tert*-butyl resonance (Figure S5). In contrast, the line-up of NOESY cross-peaks with the same *tert*-butyl signal delivered safe assignments of its PCSs. It is an advantage of the NOESY spectrum that different cross-peaks have different intensities, as this can be used to track the cross-peaks in the paramagnetic samples, as in the example of the aromatic peaks in Figure 3B. This makes the assignment of PCSs easier in 2D NOESY spectra than in 2D ^{15}N-HSQC spectra.

It is an important additional benefit that NOESY cross-peaks also deliver the PCSs of the interacting proton spins. While the PCSs of a ^{15}N−^{1}H group tend to be very similar for the ^{15}N and ^{1}H spins due to their close spatial proximity, the ^{1}H spins involved in a NOE are further apart and thus more likely to display PCSs of different magnitude. This presents highly useful information for orienting the internuclear vector relative to the $\Delta\chi$ tensor. In the case of the *tert*-butyl phenyl group of ligand **1**, PCSs were available from three different tagging sites, which unambiguously determined its orientation relative to the protein.

As is common with drug targets of moderate complexity, resonance assignments of DENpro could be obtained with reasonable effort for spectrally resolved ^{15}N-HSQC cross-peaks, whereas near-complete resonance assignments, as required for conventional NOESY cross-peak assignments, would be prohibitively laborious to establish for every complex with a new ligand. In this situation, PCSs present a much more

efficient route to structural information, as $\Delta\chi$ tensors can be determined from PCSs of a small number of resolved backbone amide peaks, which can be assigned by, e.g., systematic site-directed mutagenesis of selectively isotope-labeled samples.[50,51] While the accuracy of PCSs may be insufficient to predict close intermolecular protein−ligand contacts, the localization spaces defined by PCSs from paramagnetic tags at multiple sites greatly limit the number of possible assignments for intermolecular NOEs observed with the *tert*-butyl resonance. As shown in the present work, the residue type of the protein protons involved in the intermolecular NOEs can be ascertained by chemical shifts as well as selective isotope labeling.

In many instances, it is easier to synthesize a ligand molecule with a *tert*-butyl group than with a stable isotope, in particular as *tert*-butyl groups are part of common synthetic building blocks and protection strategies. Consequently, *tert*-butyl groups are also frequently found in fragment libraries and series of inhibitor candidates during the early phases of the drug discovery process. The *tert*-butyl moiety can establish hydro-phobic protein−ligand interactions and therefore often increases ligand affinity. It is also present in recently approved drugs, such as the HCV protease inhibitors boceprevir and telaprevir.[52] If a *tert*-butyl group is highly solvent exposed and flexible, it will produce less intense NOEs, but its ^{1}H NMR signal will be narrower, which facilitates identification of its localization space as a taller signal makes it easier to extract PCSs from 1D NMR spectra.

Ligands containing fluorine have found widespread applica-tion as NMR probes for protein−ligand studies.[16,53] In principle, the combined PCS and NOE strategy outlined in the present work could be extended to ^{1}H−^{19}F HOESY spectra, except that sensitivity would be compromised by the much broader line width of ^{19}F combined with typically fewer ^{19}F spins in the ligand molecules.

In conclusion, the combined PCS and NOE approach of the present work opens a practical and expedient route to elucidate the binding mode of high-affinity ligands in 1:1 complexes of protein targets. In contrast to studies with weakly binding ligands, no excess of ligand is required, which is an important advantage in the case of poorly soluble compounds. Detailed structural information about the protein−ligand complex can be obtained without costly perdeuteration, and dilute solutions of protein−ligand complexes with highly incomplete NMR resonance assignments can be investigated. While multiple samples with different paramagnetic tags are required to measure the PCSs and NOEs, each NMR experiment is quick and uses protein sparingly, making it practical to study a protein with a set of different ligands. The structural data that can be obtained with this strategy open a new and unique window of opportunity for the rational development of high-affinity lead compounds in drug development projects, when cocrystal structures of the protein−ligand complex cannot be obtained with acceptable effort.

■ ASSOCIATED CONTENT

ⓢ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.6b00416.

> Tables of PCSs; table of fitted $\Delta\chi$ tensor parameters; chemical structure of the C2-Ln^{3+} tag; comparison of ^{15}N-HSQC spectra of DENpro with and without ligand

1; ^{15}N-HSQC spectrum with resonance assignments; ^{15}N-HSQC spectra of DENpro tagged with C2−Y^{3+}, C2−Tm^{3+}, and C2−Tb^{3+} at different sites; 1D ^{1}H NMR spectra showing PCSs of the *tert*-butyl group of ligand **1** in complex with DENpro; RMSDs of ligand poses after Rosetta refinement; correlation between experimental and back-calculated PCSs for the final model structure of DENpro; NOESY spectra recorded with and without ^{13}C-decoupling; NOESY spectrum of DENpro Val155Ile; comparison between the structural model of the complex between DENpro and ligand **1** of the present work with the crystal structure 3U1I. (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*gottfried.otting@anu.edu.au

Notes

The authors declare no competing financial interest.

■ REFERENCES

(1) (a) Barile, E.; Pellecchia, M. *Chem. Rev.* **2014**, *114*, 4749−4763. (b) Harner, M. J.; Frank, A. O.; Fesik, S. W. *J. Biomol. NMR* **2013**, *56*, 65−75. (c) Pellecchia, M.; Sem, D. S.; Wüthrich, K. *Nat. Rev. Drug Discovery* **2002**, *1*, 211−219. (d) Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. *Q. Rev. Biophys.* **1999**, *32*, 211−240. (e) Otting, G. *Curr. Opin. Struct. Biol.* **1993**, *3*, 760−768.

(2) (a) Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. *Science* **1996**, *274*, 1531−1534. (b) Medek, A.; Hajduk, P. J.; Mack, J.; Fesik, S. W. *J. Am. Chem. Soc.* **2000**, *122*, 1241−1242.

(3) (a) Breeze, A. L. *Prog. Nucl. Magn. Reson. Spectrosc.* **2000**, *36*, 323−372. (b) Eichmüller, C.; Tollinger, M.; Kräutler, B.; Konrat, R. *J. Biomol. NMR* **2001**, *20*, 195−202.

(4) Pellecchia, M.; Meininger, D.; Dong, Q.; Chang, E.; Jack, R.; Sem, D. S. *J. Biomol. NMR* **2002**, *22*, 165−173.

(5) (a) Liu, W. M.; Overhand, M.; Ubbink, M. *Coord. Chem. Rev.* **2014**, *273−274*, 2−12. (b) Otting, G. *Annu. Rev. Biophys.* **2010**, *39*, 387−405. (c) Otting, G. *J. Biomol. NMR* **2008**, *42*, 1−9.

(6) John, M.; Pintacuda, G.; Park, A. Y.; Dixon, N. E.; Otting, G. *J. Am. Chem. Soc.* **2006**, *128*, 12910−12916.

(7) Zhuang, T.; Lee, H.-S.; Imperiali, B.; Prestegard, J. H. *Protein Sci.* **2008**, *17*, 1220−1231.

(8) Balogh, E.; Wu, D.; Zhou, G.; Gochin, M. *J. Am. Chem. Soc.* **2009**, *131*, 2821−2823.

(9) Keizers, P. H. J.; Mersinli, B.; Reinle, W.; Donauer, J.; Hiruma, Y.; Hannemann, F.; Overhand, M.; Bernhardt, R.; Ubbink, M. *Biochemistry* **2010**, *49*, 6846−6855.

(10) Saio, T.; Ogura, K.; Shimizu, K.; Yokochi, M.; Burke, T. R.; Inagaki, F. *J. Biomol. NMR* **2011**, *51*, 395−408.

(11) Guan, J.; Keizers, P. H. J.; Liu, W.; Löhr, F.; Skinner, S. P.; Heeneman, E. A.; Schwalbe, H.; Ubbink, M.; Siegal, G. *J. Am. Chem. Soc.* **2013**, *135*, 5859−5868.

(12) Saio, T.; Yokochi, M.; Kumeta, H.; Inagaki, F. *J. Biomol. NMR* **2010**, *46*, 271−280.

(13) Canales, A.; Mallagaray, A.; Berbís, M. A.; Navarro-Vázquez, A.; Domínguez, G.; Cañada, F. J.; André, S.; Gabius, H. J.; Pérez-Castells, J.; Jiménez-Barbero, J. *J. Am. Chem. Soc.* **2014**, *136*, 8011−8017.

(14) Brath, U.; Swamy, S. I.; Veiga, Z. X.; Tung, C.-C.; Van Petegem, F.; Erdélyi, M. *J. Am. Chem. Soc.* **2015**, *137*, 11391−11398.

(15) Pintacuda, G.; Park, A. Y.; Keniry, M. A.; Dixon, N. E.; Otting, G. *J. Am. Chem. Soc.* **2006**, *128*, 3696−3702.

(16) Poppe, L.; Tegley, C. M.; Li, V.; Lewis, J.; Zondlo, J.; Yang, E.; Kurzeja, R. J.; Syed, R. *J. Am. Chem. Soc.* **2009**, *131*, 16654−16655.

(17) Chen, W. N.; Loscha, K. V.; Nitsche, C.; Graham, B.; Otting, G. *FEBS Lett.* **2014**, *588*, 2206−2211.

(18) (a) Otting, G.; Wüthrich, K. *Q. Rev. Biophys.* **1990**, *23*, 39−96. (b) Zwahlen, C.; Legault, P.; Vincent, S. J. F.; Greenblatt, J.; Konrat, R.; Kay, L. E. *J. Am. Chem. Soc.* **1997**, *119*, 6711−6721. (c) Whitehead, B.; Tessari, M.; Düx, P.; Boelens, R.; Kaptein, R.; Vuister, G. W. *J. Biomol. NMR* **1997**, *9*, 313−316. (d) Sattler, M.; Schleucher, J.; Griesinger, C. *Prog. Nucl. Magn. Reson. Spectrosc.* **1999**, *34*, 93−158. (e) Andersson, P.; Otting, G. *J. Magn. Reson.* **2000**, *144*, 168−170.

(19) Hsu, V. L.; Armitage, I. M. *Biochemistry* **1992**, *31*, 12778−12784.

(20) Chen, W.-N.; Kuppan, K. V.; Lee, M. D.; Jaudzems, K.; Huber, T.; Otting, G. *J. Am. Chem. Soc.* **2015**, *137*, 4581−4586.

(21) Capeding, M. R.; Tran, N. H.; Hadinegoro, S. R.; Ismail, H. I.; Chotpitayasunondh, T.; Chua, M. N.; Luong, C. Q.; Rusmil, K.; Wirawan, D. N.; Nallusamy, R.; Pitisuttithum, P.; Thisyakorn, U.; Yoon, I. K.; van der Vliet, D.; Langevin, E.; Laot, T.; Hutagalung, Y.; Frago, C.; Boaz, M.; Wartel, T. A.; Tornieporth, N. G.; Saville, M.; Bouckenooghe, A. *Lancet* **2014**, *384*, 1358−1365.

(22) (a) Messina, J. P.; Brady, O. J.; Scott, T. W.; Zou, C.; Pigott, D. M.; Duda, K. A.; Bhatt, S.; Katzelnick, L.; Howes, R. E.; Battle, K. E.; Simmons, C. P.; Hay, S. I. *Trends Microbiol.* **2014**, *22*, 138−146. (b) Screaton, G.; Mongkolsapaya, J.; Yacoub, S.; Roberts, C. *Nat. Rev. Immunol.* **2015**, *15*, 745−759.

(23) Clum, S.; Ebner, K. E.; Padmanabhan, R. *J. Biol. Chem.* **1997**, *272*, 30715−30723.

(24) Lescar, J.; Luo, D.; Xu, T.; Sampath, A.; Lim, S.; Canard, B.; Vasudevan, S. *Antiviral Res.* **2008**, *80*, 94−101.

(25) (a) Nitsche, C.; Holloway, S.; Schirmeister, T.; Klein, C. D. *Chem. Rev.* **2014**, *114*, 11348−11381. (b) Behnam, M. A. M.; Nitsche, C.; Boldescu, V.; Klein, C. D. *J. Med. Chem.* **2016**, DOI: 10.1021/acs.jmedchem.5b01653.

(26) Erbel, P.; Schiering, N.; D'Arcy, A.; Renatus, M.; Kroemer, M.; Lim, S. P.; Yin, Z.; Keller, T. H.; Vasudevan, S. G.; Hommel, U. *Nat. Struct. Mol. Biol.* **2006**, *13*, 372−373.

(27) Noble, C. G.; Seh, C. C.; Chao, A. T.; Shi, P. Y. *J. Virol.* **2012**, *86*, 438−446.

(28) Yin, Z.; Patel, S. J.; Wang, W.-L.; Wang, G.; Chan, W.-L.; Rao, K. R.; Alam, J.; Jeyaraj, D. A.; Ngew, X.; Patel, V.; Beer, D.; Lim, S. P.; Vasudevan, S. G.; Keller, T. H. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 36−39.

(29) Nitsche, C.; Schreier, V. N.; Behnam, M. a M.; Kumar, A.; Bartenschlager, R.; Klein, C. D. *J. Med. Chem.* **2013**, *56*, 8389−8403.

(30) Lim, S. P.; Wang, Q. Y.; Noble, C. G.; Chen, Y. L.; Dong, H.; Zou, B.; Yokokawa, F.; Nilar, S.; Smith, P.; Beer, D.; Lescar, J.; Shi, P. Y. *Antiviral Res.* **2013**, *100*, 500−519.

(31) de la Cruz, L.; Nguyen, T. H. D.; Ozawa, K.; Shin, J.; Graham, B.; Huber, T.; Otting, G. *J. Am. Chem. Soc.* **2011**, *133*, 19205−19215.

(32) Kim, Y. M.; Gayen, S.; Kang, C.; Joy, J.; Huang, Q.; Chen, A. S.; Wee, J. L.; Ang, M. J.; Lim, H. A.; Hung, A. W.; Li, R.; Noble, C. G.; Lee, L. T.; Yip, A.; Wang, Q.-Y.; Chia, C. S. B.; Hill, J.; Shi, P.-Y.; Keller, T. H. *J. Biol. Chem.* **2013**, *288*, 12891−12900.

(33) Bi, Y.; Zhu, L.; Li, H.; Wu, B.; Liu, J.; Wang. *Biomol. NMR Assignments* **2013**, *7*, 137−139.

(34) Li, H.; Zhu, L.; Hou, S.; Yang, J.; Wang, J.; Liu, J. *FEBS Lett.* **2014**, *588*, 2794−2799.

(35) de la Cruz, L.; Chen, W. N.; Graham, B.; Otting, G. *FEBS J.* **2014**, *281*, 1517−1533.

(36) Graham, B.; Loh, C. T.; Swarbrick, J. D.; Ung, P.; Shin, J.; Yagi, H.; Jia, X.; Chhabra, S.; Barlow, N.; Pintacuda, G.; Huber, T.; Otting, G. *Bioconjugate Chem.* **2011**, *22*, 2118−2125.

(37) Bertini, I.; Luchinat, C.; Parigi, G. *Prog. Nucl. Magn. Reson. Spectrosc.* **2002**, *40*, 249−273.

(38) Pilla, K. B.; Leman, J. K.; Otting, G.; Huber, T. *PLoS One* **2015**, *10*, e0127053.

(39) Šali, A.; Blundell, T. L. *J. Mol. Biol.* **1993**, *234*, 779−815.

(40) Webb, B.; Sali, A. In *Protein Structure Prediction*; Springer, 2014; pp 1−15.

(41) Shen, M.; Sali, A. *Protein Sci.* **2006**, *15*, 2507−2524.

(42) Trott, O.; Olson, A. J. *J. Comput. Chem.* **2010**, *31*, 455−461.

(43) Conway, P.; Tyka, M. D.; DiMaio, F.; Konerding, D. E.; Baker, D. *Protein Sci.* **2014**, *23*, 47−55.

(44) Venkatraman, S.; Wu, W.; Prongay, A.; Girijavallabhan, V.; Njoroge, F. G. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 180−183.

(45) www.rosettacommons.org/demos/latest/public/relax_around_chemically_bound_ligand/README, accessed 1 Nov. 2014.

(46) Schmitz, C.; Vernon, R.; Otting, G.; Baker, D.; Huber, T. *J. Mol. Biol.* **2012**, *416*, 668−677.

(47) Bleaney, B. *J. Magn. Reson.* **1972**, *8*, 91−100.

(48) Vega, A. J.; Fiat, D. *Mol. Phys.* **1976**, *31*, 347−355.

(49) Pintacuda, G.; Kaikkonen, A.; Otting, G. *J. Magn. Reson.* **2004**, *171*, 233−243.

(50) Wu, P. S. C.; Ozawa, K.; Lim, S. P.; Vasudevan, S. G.; Dixon, N. E.; Otting, G. *Angew. Chem., Int. Ed.* **2007**, *46*, 3356−3358.

(51) Abdelkader, E. H.; Yao, X.; Feintuch, A.; Adams, L. A.; Aurelio, L.; Graham, B.; Goldfarb, D.; Otting, G. *J. Biomol. NMR* **2016**, *64*, 39−51.

(52) De Luca, A.; Bianco, C.; Rossetti, B. *Curr. Opin. Pharmacol.* **2014**, *18*, 9−17.

(53) Vulpetti, A.; Dalvit, C. *Drug Discovery Today* **2012**, *17*, 890−897.